Marc Paradé

520 total citations
8 papers, 150 citations indexed

About

Marc Paradé is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Marc Paradé has authored 8 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Oncology. Recurrent topics in Marc Paradé's work include Phagocytosis and Immune Regulation (2 papers), FOXO transcription factor regulation (2 papers) and Immunotherapy and Immune Responses (2 papers). Marc Paradé is often cited by papers focused on Phagocytosis and Immune Regulation (2 papers), FOXO transcription factor regulation (2 papers) and Immunotherapy and Immune Responses (2 papers). Marc Paradé collaborates with scholars based in Belgium, United Kingdom and Netherlands. Marc Paradé's co-authors include Dirk Brehmer, Joost A.P. Rens, Paul Vink, Joannes T. M. Linders, Andrea van Elsas, Inge Reinieren-Beeren, Peter van Zandvoort, Joost H. C. M. Kreijtz, Sanne Spijkers and Hans van Eenennaam and has published in prestigious journals such as PLoS ONE, Cancer Research and Annals of Oncology.

In The Last Decade

Marc Paradé

7 papers receiving 147 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Paradé Belgium 5 86 64 22 18 17 8 150
Ronald Rudolf Germany 6 87 1.0× 128 2.0× 29 1.3× 17 0.9× 22 1.3× 8 197
Katharina Urban Germany 5 62 0.7× 40 0.6× 30 1.4× 9 0.5× 18 1.1× 6 127
Ujunwa Cynthia Okoye-Okafor United States 4 119 1.4× 46 0.7× 19 0.9× 10 0.6× 16 0.9× 5 176
Chad Whilding United Kingdom 9 222 2.6× 68 1.1× 19 0.9× 16 0.9× 18 1.1× 13 294
Veronica M. Pravatà United Kingdom 7 160 1.9× 83 1.3× 22 1.0× 36 2.0× 26 1.5× 9 205
Eduardo Zarzuela Spain 10 164 1.9× 19 0.3× 28 1.3× 12 0.7× 11 0.6× 15 202
María Pérez-Lanzón France 8 106 1.2× 62 1.0× 91 4.1× 14 0.8× 26 1.5× 14 211
Martin Prete United Kingdom 4 113 1.3× 33 0.5× 23 1.0× 6 0.3× 27 1.6× 4 153
Alexandra Just Germany 2 90 1.0× 32 0.5× 61 2.8× 10 0.6× 36 2.1× 4 170
Michaela C. Baldauf Germany 5 136 1.6× 21 0.3× 36 1.6× 9 0.5× 41 2.4× 7 197

Countries citing papers authored by Marc Paradé

Since Specialization
Citations

This map shows the geographic impact of Marc Paradé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Paradé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Paradé more than expected).

Fields of papers citing papers by Marc Paradé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Paradé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Paradé. The network helps show where Marc Paradé may publish in the future.

Co-authorship network of co-authors of Marc Paradé

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Paradé. A scholar is included among the top collaborators of Marc Paradé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Paradé. Marc Paradé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Paradé, Marc, et al.. (2021). 129P BYON4228 is a pan-allelic SIRPα antibody that potentiates killing of antibody-opsonized tumor cells and lacks binding to T-cells. Annals of Oncology. 32. S1433–S1434. 1 indexed citations
2.
Duijnhoven, Sander M. J. van, Marc Paradé, Dietmar M. Zaiss, et al.. (2021). Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies. Journal of Immunological Methods. 499. 113173–113173. 1 indexed citations
3.
Pande, Vineet, Weimei Sun, Lijs Beke, et al.. (2020). A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode. ACS Medicinal Chemistry Letters. 11(11). 2227–2231. 12 indexed citations
4.
Voets, Erik, Marc Paradé, D. Lutje Hulsik, et al.. (2019). Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint. Journal for ImmunoTherapy of Cancer. 7(1). 340–340. 56 indexed citations
5.
Wandinger, Sebastian K., Idoya Lahortiga, Kris Jacobs, et al.. (2016). Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling. PLoS ONE. 11(1). e0146100–e0146100. 13 indexed citations
6.
Beke, Lijs, Cenk Kığ, Joannes T. M. Linders, et al.. (2015). MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Bioscience Reports. 35(6). 58 indexed citations
7.
Beke, Lijs, Joannes T. M. Linders, Cenk Kığ, et al.. (2014). Abstract 2936: JNJ-47117096, a selective small molecule inhibitor of the MELK oncogene decreases DNA damage tolerance in highly proliferating cancer cells. Cancer Research. 74(19_Supplement). 2936–2936.
8.
Gerrits, Han, et al.. (2013). Reversible infertility in a liver receptor homologue-1 (LRH-1)-knockdown mouse model. Reproduction Fertility and Development. 26(2). 293–306. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026